FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906932889> ?p ?o ?g. }

• W2906932889 endingPage "300" @default.
• W2906932889 startingPage "293" @default.
• W2906932889 abstract "Abstract Sinonasal intestinal-type adenocarcinomas (SNS-ITAC) are very rare tumors that resemble colorectal cancer in many of their pathological and molecular characteristics. Indeed, in most published series, 10%–14% of SNS-ITAC harbor mutations in KRAS. There is no standard systemic treatment in recurrent or metastatic SNS-ITAC, and there is no evidence of the use of any targeted agent in this entity. We present the case of a recurrent nasoethmoidal ITAC informed as RAS and BRAF wild-type by standard real-time polymerase chain reaction methods and treated with first-line cetuximab and irinotecan without response. Circulating tumor cells coupled to highly sensitive DNA analyses unveiled a mutation in KRAS exon 2 codon 12. Subsequent studies in the primary tumor using BEAMing detected a mutation in the same codon, confirming the KRAS mutated status of the tumor, and possibly explaining the absence of treatment response. This case exemplifies how liquid biopsy can aid in the correct and real-time molecular characterization of tumors even in a rare nonmetastatic cancer of the head and neck. Key Points Sinonasal intestinal type adenocarcinomas (SNS-ITAC) are rare tumors that commonly develop after a prolonged exposure to organic dusts (wood, leather, etc.), and that resemble colorectal cancer in some of their morphological and molecular characteristics. KRAS mutations have been described in 10%–14% in most series. However, its predictive value for guiding treatment decisions with targeted therapies (i.e., anti-epidermal growth factor receptor [EGFR] therapy) has not been defined. The first case of an SNS-ITAC treated with anti-EGFR therapy (cetuximab) is reported. Analysis of DNA from circulating tumor cells (CTCs) unveiled a mutation in KRAS not detected by standard methods in the primary tumor. However, RAS analysis using BEAMing detected a mutation in the primary tumor in the same codon of KRAS originally detected in CTCs, altogether possibly explaining the lack of treatment response. Liquid biopsy may allow for an accurate molecular diagnosis in rare, organ-confined tumors where few therapeutic options exist. Highly sensitive molecular diagnostics may aid in better characterizing rare entities harboring potentially druggable targets." @default.
• W2906932889 created "2019-01-11" @default.
• W2906932889 creator A5007291981 @default.
• W2906932889 creator A5011398429 @default.
• W2906932889 creator A5014016108 @default.
• W2906932889 creator A5035580666 @default.
• W2906932889 creator A5037481195 @default.
• W2906932889 creator A5043252019 @default.
• W2906932889 creator A5049615075 @default.
• W2906932889 creator A5050079233 @default.
• W2906932889 creator A5061888718 @default.
• W2906932889 creator A5070615926 @default.
• W2906932889 date "2019-01-02" @default.
• W2906932889 modified "2023-10-18" @default.
• W2906932889 title "Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy" @default.
• W2906932889 cites W1638528055 @default.
• W2906932889 cites W1969020720 @default.
• W2906932889 cites W1973916350 @default.
• W2906932889 cites W1983245831 @default.
• W2906932889 cites W1992826811 @default.
• W2906932889 cites W1993631154 @default.
• W2906932889 cites W2005348280 @default.
• W2906932889 cites W2006168411 @default.
• W2906932889 cites W2008560474 @default.
• W2906932889 cites W2013604487 @default.
• W2906932889 cites W2015132197 @default.
• W2906932889 cites W2015438948 @default.
• W2906932889 cites W2032808490 @default.
• W2906932889 cites W2034035592 @default.
• W2906932889 cites W2052352402 @default.
• W2906932889 cites W2054424062 @default.
• W2906932889 cites W2058478456 @default.
• W2906932889 cites W2062109911 @default.
• W2906932889 cites W2073146203 @default.
• W2906932889 cites W2073823657 @default.
• W2906932889 cites W2076781058 @default.
• W2906932889 cites W2084968536 @default.
• W2906932889 cites W2095647475 @default.
• W2906932889 cites W2108235590 @default.
• W2906932889 cites W2112570485 @default.
• W2906932889 cites W2113248685 @default.
• W2906932889 cites W2116731538 @default.
• W2906932889 cites W2121869934 @default.
• W2906932889 cites W2138143000 @default.
• W2906932889 cites W2145957615 @default.
• W2906932889 cites W2147287888 @default.
• W2906932889 cites W2169715257 @default.
• W2906932889 cites W2174570955 @default.
• W2906932889 cites W2258730239 @default.
• W2906932889 cites W2283604962 @default.
• W2906932889 cites W2297086669 @default.
• W2906932889 cites W2395152127 @default.
• W2906932889 cites W2409551698 @default.
• W2906932889 cites W2464728687 @default.
• W2906932889 cites W2602324018 @default.
• W2906932889 cites W2622499649 @default.
• W2906932889 cites W2744428642 @default.
• W2906932889 cites W2760535960 @default.
• W2906932889 cites W2773722618 @default.
• W2906932889 cites W2793362544 @default.
• W2906932889 cites W3186245918 @default.
• W2906932889 doi "https://doi.org/10.1634/theoncologist.2018-0387" @default.
• W2906932889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6519763" @default.
• W2906932889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30602616" @default.
• W2906932889 hasPublicationYear "2019" @default.
• W2906932889 type Work @default.
• W2906932889 sameAs 2906932889 @default.
• W2906932889 citedByCount "7" @default.
• W2906932889 countsByYear W29069328892019 @default.
• W2906932889 countsByYear W29069328892020 @default.
• W2906932889 countsByYear W29069328892021 @default.
• W2906932889 countsByYear W29069328892022 @default.
• W2906932889 countsByYear W29069328892023 @default.
• W2906932889 crossrefType "journal-article" @default.
• W2906932889 hasAuthorship W2906932889A5007291981 @default.
• W2906932889 hasAuthorship W2906932889A5011398429 @default.
• W2906932889 hasAuthorship W2906932889A5014016108 @default.
• W2906932889 hasAuthorship W2906932889A5035580666 @default.
• W2906932889 hasAuthorship W2906932889A5037481195 @default.
• W2906932889 hasAuthorship W2906932889A5043252019 @default.
• W2906932889 hasAuthorship W2906932889A5049615075 @default.
• W2906932889 hasAuthorship W2906932889A5050079233 @default.
• W2906932889 hasAuthorship W2906932889A5061888718 @default.
• W2906932889 hasAuthorship W2906932889A5070615926 @default.
• W2906932889 hasBestOaLocation W29069328891 @default.
• W2906932889 hasConcept C121608353 @default.
• W2906932889 hasConcept C126322002 @default.
• W2906932889 hasConcept C142724271 @default.
• W2906932889 hasConcept C143998085 @default.
• W2906932889 hasConcept C2779438470 @default.
• W2906932889 hasConcept C2779529041 @default.
• W2906932889 hasConcept C2779998722 @default.
• W2906932889 hasConcept C2781182431 @default.
• W2906932889 hasConcept C2781187634 @default.
• W2906932889 hasConcept C2781230642 @default.
• W2906932889 hasConcept C502942594 @default.
• W2906932889 hasConcept C526805850 @default.
• W2906932889 hasConcept C71924100 @default.

• next